{"nctId":"NCT01217892","briefTitle":"Evaluation of Dapagliflozin Taken Twice-daily","startDateStruct":{"date":"2010-11"},"conditions":["Type 2 Diabetes"],"count":400,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: metformin"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: metformin"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: metformin"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: metformin","Drug: placebo"]}],"interventions":[{"name":"dapagliflozin","otherNames":[]},{"name":"dapagliflozin","otherNames":[]},{"name":"dapagliflozin","otherNames":[]},{"name":"metformin","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of T2DM\n* Current antihyperglycaemic treatment with metformin immediate release formulation monotherapy \\>/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. Other treatment with OADs within the 10 weeks prior to enrolment is not permitted.\n* HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and Enrolment Visit 1.\n\nExclusion Criteria:\n\n* Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of the Young (MODY) or secondary causes of diabetes mellitus\n* History of diabetic ketoacidosis\n* Symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment\n* FPG \\>270 mg/dL (\\>15.0 mmol/L)\n* BMI \\>45 kg/m2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To compare the change from baseline in HbA1c achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.0594"},{"groupId":"OG001","value":"-0.65","spread":"0.0600"},{"groupId":"OG002","value":"-0.59","spread":"0.0598"},{"groupId":"OG003","value":"-0.30","spread":"0.0593"}]}]}]},{"type":"SECONDARY","title":"Adjusted Percent Change in Body Weight","description":"To compare the percent change from baseline in body weight achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID, and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.84","spread":"0.3099"},{"groupId":"OG001","value":"-3.20","spread":"0.3125"},{"groupId":"OG002","value":"-2.76","spread":"0.3086"},{"groupId":"OG003","value":"-1.04","spread":"0.3105"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 1","description":"To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 1 week of double-blind treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.7","spread":"2.657"},{"groupId":"OG001","value":"-14.7","spread":"2.672"},{"groupId":"OG002","value":"-15.5","spread":"2.634"},{"groupId":"OG003","value":"2.0","spread":"2.584"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16","description":"To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.8","spread":"2.738"},{"groupId":"OG001","value":"-25.6","spread":"2.759"},{"groupId":"OG002","value":"-20.4","spread":"2.720"},{"groupId":"OG003","value":"-10.4","spread":"2.669"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HbA1c<7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.","description":"To compare the adjusted proportions controlling for baseline HbA1c \\[acc. to Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu\\] of participants with HbA1c \\<7.0% achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment, in patients who had HbA1c ≥7.0% at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":null},{"groupId":"OG001","value":"38.2","spread":null},{"groupId":"OG002","value":"28.1","spread":null},{"groupId":"OG003","value":"21.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":100},"commonTop":["HYPERTENSION","INFLUENZA"]}}}